Literature DB >> 2174225

Neuropeptide Y receptor subtypes, Y1 and Y2.

C Wahlestedt1, L Grundemar, R Håkanson, M Heilig, G H Shen, Z Zukowska-Grojec, D J Reis.   

Abstract

Heterogeneity among NPY (and PYY) receptors was first proposed on the basis of studies on sympathetic neuroeffector junctions, where NPY (and PYY) can exert three types of action: 1) a direct (e.g., vasoconstrictor) response; 2) a postjunctional potentiating effect on NE-evoked vasoconstriction; and 3) a prejunctional suppression of stimulated NE release; the two latter phenomena are probably reciprocal, since NE affect NPY mechanisms similarly. It was found that amidated C-terminal NPY (or PYY) fragments, e.g., NPY 13-36, could stimulate selectively prejunctional NPY/PYY receptors, which were termed Y2-receptors. Consequently, the postjunctional receptors which were activated poorly by NPY/PYY fragments, were termed Y1-receptors. Later work has indicated that the Y2-receptor may occur postjunctionally in selected sympathetic effector systems. The central nervous system appears to contain a mixture of Y1- and Y2-receptors as indicated by functional as well as binding studies. For instance, NPY and NPY 13-36 produced diametrically opposite effects on behavioral activity, indicating the action of the parent peptide on two distinct receptors. Cell lines, most importantly neuroblastomas, with exclusive populations of Y1- or Y2-receptors, have been characterized by binding and second messenger studies. In this work, selective agonists for the two receptor subtypes were used. Work of many investigators has formed the basis for subclassifying NPY/PYY effects being mediated by either Y1- or Y2-receptors. A preliminary subclassification based on effects of NPY, PYY, fragments and/or analogs is provided in Table 6. It is, however, to be expected that further receptor heterogeneity will be revealed in the future. It is argued that mast cells possess atypical NPY/PYY receptors. The histamine release associated with stimulation of the latter receptors may, at least in part, underlie the capacity of NPY as well as of short C-terminal fragments to reduce blood pressure. Fragments, such as NPY 22-36, appear to be relatively selective vasodepressor agents because of their weak vasopressor properties.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2174225     DOI: 10.1111/j.1749-6632.1990.tb48918.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  29 in total

1.  Neuropeptide Y, peptide YY and C-terminal fragments release histamine from rat peritoneal mast cells.

Authors:  L Grundemar; R Håkanson
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

2.  NPY receptors as potential targets for anti-obesity drug development.

Authors:  Ernie Yulyaningsih; Lei Zhang; Herbert Herzog; Amanda Sainsbury
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

3.  Multiple NPY receptors coexist in pre- and postsynaptic sites: inhibition of GABA release in isolated self-innervating SCN neurons.

Authors:  G Chen; A N van den Pol
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

4.  Colonic responses to enteral tube feeding.

Authors:  T E Bowling; D B Silk
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

5.  Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.

Authors:  M Tschöpl; R C Miller; J Pelton; J C Stoclet; B Bucher
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Evoked noradrenaline release in the rabbit ear artery: enhancement by purines, attenuation by neuropeptide Y and lack of effect of calcitonin gene-related peptide.

Authors:  K I Maynard; G Burnstock
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Strong evolutionary conservation of neuropeptide Y: sequences of chicken, goldfish, and Torpedo marmorata DNA clones.

Authors:  A G Blomqvist; C Söderberg; I Lundell; R J Milner; D Larhammar
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

8.  Peptide YY selectively stimulates expression of the colonocytic phenotype.

Authors:  S A Sgambati; G A Turowski; M D Basson
Journal:  J Gastrointest Surg       Date:  1997 Nov-Dec       Impact factor: 3.452

9.  Localization and characterization of neuropeptide Y binding sites in porcine and human colon.

Authors:  D A Walsh; J Wharton; D R Blake; J M Polak
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

Review 10.  Neuropeptide Y and neurovascular control in skeletal muscle and skin.

Authors:  Gary J Hodges; Dwayne N Jackson; Louis Mattar; John M Johnson; J Kevin Shoemaker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-07-01       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.